RXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
|
|
- Shana Caldwell
- 5 years ago
- Views:
Transcription
1 RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII
2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of Words such as believes, anticipates, plans, expects, indicates, will, intends, potential, suggests and similar expressions are intended to identify forward-looking statements. These statements are based on RXi Pharmaceuticals Corporation s (the Company ) current beliefs and expectations. Such statements include, but are not limited to, statements about the future development of the Company s products (including timing of clinical trials and related matters associated therewith), the expected timing of certain developmental milestones, the reporting of unblinded data, potential partnership opportunities, the Company s competition and market opportunity and pro forma estimates. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this presentation due to risks and uncertainties in the Company s business, including those identified under Risk Factors in the Company s most recently filed Quarterly Report on Form 10-Q and in other filings the Company periodically makes with the U.S. Securities and Exchange Commission. The Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. 2
3 RNAi Mechanism Results in Potent Gene Silencing RNAi is a naturally occurring biological process which can be harnessed to silence the expression of a specific disease protein. For each targeted mrna destroyed, 10s-100s of disease proteins are NOT made. 1 RNAi compound (sd-rxrna) administered 2 sd-rxrna enters cells mrna sd-rxrna RISC 4 Target mrna is cut & destroyed cleaved mrna cell membrane 3 sd-rxrna loads into RNA-induced silencing complex (RISC) Disease protein expression is blocked 3
4 Novel Self-delivering RNAi (sd-rxrna ) Platform 4 Provides for Broad Pipeline of RNAi Drugs for Unmet Medical Needs Single compound incorporates gene silencing activity & cellular uptake Robust uptake & silencing in multiple preclinical models Demonstration of safety and activity in a clinical setting Delivery is not limited to a specific cell-type Can be used alone or in combination with cell-based therapeutics Best RNAi technology for enhancement of cell-based therapeutics Potential to expand cell therapy beyond its current reach, e.g. CAR-T cells for solid tumors Freedom to operate with broad IP protection 4
5 RXi Pharmaceuticals Development Pipeline Internal development of Immuno-oncology therapeutics for high unmet medical needs with multi-billion dollar market potential. Aiming to enter the clinic within next months. Target Indication Disc. Preclin. P1 P2 P3 *In ACT RXI-762 PD-1* Solid tumors RXI-804 TIGIT* Solid Tumors Undisclosed (3 products) Undisclosed Undisclosed Expanding internal development efforts and external collaborations with various existing cell-based approaches, evaluating hematopoietic stem cells, NK cells, TILs, CAR T, TCR and engineered NK cells to accelerate growth and develop immuno-oncology targets beyond checkpoint inhibition, i.e. cell differentiation. 5
6 Immunosuppression Major Hurdle for ACT in Solid Tumors Initial clinical trials of CAR T in solid tumors show limited success One of the major issues is immunosuppressive tumor microenvironment Multiple inhibitory receptors - immune checkpoints - are responsible for immunosuppression Clinical and commercial success of monoclonal antibodies targeting PD-1/PD- L1, CTLA-4 validate checkpoint targeting approach Challenging to use antibodies to target multiple checkpoints sd-rxrna proven multitargeting approach in single therapeutic entity 6 Immune Checkpoints: (D. Pardoll, Nature Rev. Cancer, 2012)
7 sd-rxrna in Adoptive Cell Transfer Modulation of Immune Effector Cells with RNAi Checkpoint Inhibition sd-rxrna pre-treatment of cells can be used to silence one or more immuno-suppressive genes (such as PD-1 and other checkpoints). Results in fewer suppressive receptors on the immune cell surface, which boosts their ability to detect and destroy tumor cells. 7
8 sd-rxrna: Best RNAi technology for ACT High Transfection Efficiency with High Cell Viability Nearly 100% transfection efficiency combined with high cell viability 98.6% sd-rxrna 8
9 Efficient uptake of sd-rxrna (red) to Immune Cells Human T Cells Meso CAR T Human NK Cells Dendritic Cells 9
10 Broad Applicability of sd-rxrna Empower existing clinical treatment paradigms and expand applicability of engineered cells Human T Cells Number one Number two Number three TILs for ovarian cancer or melanoma HSCT for modulation of GvHD γ/δ T cells Human NK Cells Autologous or Allogeneic Natural Killer (NK) cells Cytokine Induced Killer (CIK) cells Engineered NK or CIK Engineered T Cells Number one Number two Number three CAR T TCR Checkpoint inhibition and optimization for persistence and fitness of T cells Dendritic Cells Dendritic cell cancer vaccines 10
11 Targeting Multiple Immunosuppression Pathways* in a Single Therapeutic Entity Simultaneous Silencing of Multiple Genes is a Major Competitive Advantage of sd-rxrna PD-1 *Extracellular TIGIT LAG-3 *Intracellular Undisclosed Target Gene Expression, % of non-targeting control (NTC)
12 Immuno-Oncology Clinical Development with sd-rxrna Two self-delivering RNAi (sd-rxrna ) compounds selected for preclinical development RXI-762, sd-rxrna targeting PD-1 RXI-804, sd-rxrna targeting TIGIT Manufacturing facility selected to initiate production of cgmp grade material, initially for RXI-762 to support moving into clinical development in 12 to 18 months as part of an ACT therapy. 12
13 Reduction of PD-1 Expression in Human Primary T-cells Expression of PD-1 was Measured by FACS in Intact and Permeabilized Cells Extracellular extracellular PD-1 PD-1 RPMI 8000 ** ** ** Intracellular PD-1 intracellular PD-1 RPMI * ** MFI 4000 MFI no beads no beads beads no sd-rxrna sdrna beads no sd-rxrna beads NT C1+2+3fm beads NTC beads PD78fm beads PD-1 beads NT C1+2+3fm beads NTC beads PD78fm beads PD-1 beads NT C1+2+3fm beads NTC beads PD78fm beads PD-1 0 no beads no beads beads no sdrna beads no sd-rxrna beads NT C1+2+3fm beads NTC beads PD78fm beads PD-1 beads NT C1+2+3fm beads NTC beads PD78fm beads PD-1 beads NT C1+2+3fm beads NTC beads PD78fm beads PD µm u M 1 um µm 2 um µm 0.5 µm µm u M 1 µm um 2 um µm 13
14 Meso-CAR T Construct for in vivo Studies Specific Tumor Cell Killing by Meso CAR T in vitro Mesothelin CAR Construct Construct is based on the 28z vector design seen in Carpentio, et. al. (PNAS 2009, 106:9, ). Specific Tumor Cell Killing by Meso CAR T Measured by Impedance Assay E:T ratio of 5:1 14
15 Silencing by sd-rxrna: Long-Term Effect in vivo Reduced in vivo Tumor Growth Using CAR T-cells Treated ex vivo with PD1 targeting sd-rxrna Meso CAR T-cells 1 : T-cells engineered to target mesothelin, overexpressed on many solid tumors Meso CAR T-cells were pretreated with sd-rxrna ex vivo and injected into human ovarian cancer tumors in mice * Pvalue <0.01 (compared to PBS control arm) * Reduction of tumor growth is significantly improved by anti- PD1 sd-rxrna treatment at one month Anti-PD1 sd-rxrna Control 1 CAR T-cells = chimeric antigen receptor T-cells 15
16 sd-rxrna in Cell Therapy sd-rxrna Induced PD-1 Silencing Present After 1 Month in vivo Mouse xenograft model of ovarian cancer Tumors harvested after one month and human CD45-expressing cells were extracted and analyzed for PD-1 expression by flowcytometry sd-rxrna sd-rxrna 16
17 PD1 Silencing by sd-rxrna in TILs Enhances Killing of Autologous Tumor Cells In Vitro Tumor Infiltrating Lymphocytes (TILs) Against Melanoma TILs isolated from melanoma patient TILs treated with PD1 sd-rxrna in a clinically used Rapid Expansion Protocol (REP) 17 Tumor cell killing by TILs was measured by chromium release assay in vitro Control PD-1 2uM PD-1 5uM Anti-PD-1 mab 10ug/ml 17
18 PD-1 Silenced TILs Produce Higher Amount of IFN-γ During Co-Culture with Autologous Melanoma Tumor Cells Anti-PD-1 sd-rxrna Increases IFN-γ+TNF-α+ Tumor-Specific Cytotoxic T- cells During TIL Co-culture with Autologous Tumor Cells PD-1 Silenced TILs Produce More IFN-γ TIL + KADA 24 H Control no sd-rxrna Anti-PD-1 2 µm sd-rxrna 2 µm IFN -γ (p g/m l) TNF-α 0 no sdrna NTC1+2+3fm 2 um PD78fm 2 um no sdrna NTC1+2+3fm 2 um PD78fm 2 um n o s d R N A NTC1+2+3fm 2 um P D 7 8 fm 2 u M IFN-γ effector:target 20:1 effector:target 10:1 effector:target 5:1 18
19 Benefits of Using sd-rxrna in ACT sd-rxrna Gene Editing Antibodies No direct off-tumor side effects No persisting rogue cells in the body * Moderate cost of goods Targeting multiple checkpoints *Potentially further complicated by increased evidence of off-target mutations - Schaefer, K. A., Wu, W., Colgan, D.F., Tsang, S.H, Bassuk, A.G., & Mahajan, V.B. (2017). Unexpected mutations after CRISPR Cas9 editing in vivo. Nature Methods, 14, doi: /nmeth
20 Additional Advantages with sd-rxrna in ACT Single Therapeutic Agent Single therapeutic agent with one or multiple immune checkpoints or differentiation targets attenuated Streamlined Regulatory Path Ex vivo application of sd-rxrna No multiple combination clinical trials required Newly discovered checkpoint targets or differentiation targets can be rapidly tackled Clinically proven safety of sd-rxrna Ease of Manufacturing Only small alterations needed in cell manufacturing process Facilitates adaptation of existing cell technologies 20
21 Summary of Immuno-oncology Franchise sd-rxrna for Cancer Therapeutics Best RNAi technology for ACT Can target multiple immunosuppression pathways in a single therapeutic entity Demonstrated efficient uptake of sd-rxrna to immune cells Silencing by sd-rxrna - long-term effect in vivo Clinically proven safety of sd-rxrna Ideal technology to affect cell differentiation during manufacturing Numerous ongoing collaborations evaluating hematopoietic stem cells, NK cells, TILS, CAR T, TCR and engineered NK cells RXI-762 and RXI-804 Solid Tumors sd-rxrna compounds targeting PD-1 and TIGIT respectively Established manufacturing of cgmp 21
Developing the next generation of immuno-oncology therapeutics
Developing the next generation of immuno-oncology therapeutics Biotech Showcase 2019 January 7 th, 2019 San Francisco, CA www.phiopharma.com NASDAQ: PHIO This presentation contains forward-looking statements
More informationRXi Pharmaceuticals. Biotech Showcase. San Francisco, CA. January 8, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Biotech Showcase San Francisco, CA January 8, 2018 NASDAQ: RXII Property of RXi Pharmaceuticals Forward Looking Statements This presentation contains forward-looking statements within
More informationRXi Pharmaceuticals. October 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals October 2017 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationRXi Pharmaceuticals. sd-rxrna Demonstrate Robust Efficacy in the Eye. Dr. Geert Cauwenbergh President & CEO OTCQX: RXII. Next Generation in RNAi
RXi Pharmaceuticals sd-rxrna Demonstrate Robust Efficacy in the Eye Next Generation in RNAi Dr. Geert Cauwenbergh President & CEO OTCQX: RXII 2 Forward Looking Statements This presentation contains forward-looking
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationRXi Pharmaceuticals. Building leadership in RNAi and Immunotherapy. Research Note.
Research Note RXi Pharmaceuticals Building leadership in RNAi and Immunotherapy Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 8489 2954 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationThe Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018
The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about
More informationACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy
ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationCapricor Therapeutics
Therapeutics Conference Call to Discuss the HOPE-2 Clinical Trial NASDAQ: CAPR November 29, 2017 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended
More informationRXi Pharmaceuticals. Bio Investor Forum San Francisco, CA NASDAQ: RXII. October 21, Property of RXi Pharmaceuticals
RXi Pharmaceuticals NASDAQ: RXII Bio Investor Forum San Francisco, CA October 21, 2015 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationTHERAPEUTIC IMPLICATIONS OF PREPARING AND ADMINISTERING INNATE IMMUNE CELLS. 9:40 am to 10:10 pm Laurence Cooper
THERAPEUTIC IMPLICATIONS OF PREPARING AND ADMINISTERING INNATE IMMUNE CELLS 9:40 am to 10:10 pm Laurence Cooper ljncooper@ziopharm.com 05-16-2016 Forward-looking statements This presentation contains certain
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationA Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions
A Biopharmaceutical Company Focused on Controlled Immunotherapies and Point-of-Care Solutions Second Quarter 2017 Company Update and Financial Results July 31, 2017 2 Forward-Looking Statements This presentation
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
December 4, 2018 Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting - Key highlights include near universal engraftment
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationQuarterly Update & ASH 2017 Abstract Conference Call
Quarterly Update & ASH 2017 Abstract Conference Call November 1, 2017 Nasdaq : BLUE 1 Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationCAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris
CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th 2018 - Paris Cellectis, 05-APR-2018 2 FORWARD-LOOKING STATEMENTS THIS PRESENTATION
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationHeat Biologics. Corporate Presentation March 9, 2018
Heat Biologics Corporate Presentation March 9, 2018 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements within the meaning of the Private
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationCOMPANY OVERVIEW. June CytomX Therapeutics, Inc.
COMPANY OVERVIEW June 2016 2016 CytomX Therapeutics, Inc. Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking
More informationCEL-SCI Corporation. NYSE American: CVM
CEL-SCI Corporation NYSE American: CVM Geert Kersten Chief Executive Officer 8229 Boone Boulevard, Suite 802 Vienna, VA 22182, USA Phone: (703) 506-9460 Forward Looking Statements This presentation includes
More informationThe Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy
The Galectin-3 Inhibitor GR-MD-02 for Combination Cancer Immunotherapy Supplemental Information to Corporate Presentation February 6, 2018 NASDAQ: GALT www.galectintherapeutics.com 2018 2017 Galectin Therapeutics
More informationThe Tumor Microenvironment Company
The Tumor Microenvironment Company June 2018 Legal Disclaimer This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.
More informationTumor Antigens in the Age of Engineered T cell Therapies
Tumor Antigens in the Age of Engineered T cell Therapies September 30 th 2016 ESMO Preceptorship Course Amsterdam Carsten Linnemann, PhD Senior Scientist Kite Pharma EU B.V. Amsterdam Forward Looking Statements/Safe
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationCorporate Presentation November Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation November 2015 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary
More informationONCOSEC ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS
ONCOSEC TM ARMING THE IMMUNE SYSTEM TO FIGHT CANCER NASDAQ: ONCS 0 Forward Looking Statements Our commentary and responses to your questions may contain forward looking statements, as described in the
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationNovel Approaches to CAR-T Cell Platform
Novel Approaches to CAR-T Cell Platform Vita Golubovskaya, Ph.D. Director, R&D Promab Biotechnologies 3 rd CAR-TCR Summit 2017 S E P T E M B E R 5-7 B O S T O N Novel Approaches To CAR-T Cell Platform
More informationDCVax Novel Personalized Immunotherapies for Solid Tumors
DCVax Novel Personalized Immunotherapies for Solid Tumors Phaciliate Immunotherapy World Forum January 26, 2016 Disclaimer Certain statements made in this presentation are forward-looking statements of
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationCompany Presentation. September 2018 NASDAQ: VBLT
Company Presentation September 2018 NASDAQ: VBLT Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vascular Biogenics
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationNKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology
plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationCorporate Presentation Asia Investment Series March 2018
Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationCloudbreak. March Cidara Therapeutics
Cloudbreak March 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationCreating transformative gene-based medicines for serious diseases
Creating transformative gene-based medicines for serious diseases Corporate Overview November 2018 1 Forward-Looking Statements The presentation and other related materials may contain a number of forward-looking
More informationPosters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationRNAi in HBV, the next backbone therapy for use in combinations? Bruce D. Given, MD COO, Arrowhead Pharmaceuticals L.I.F.E.R.
RNAi in HBV, the next backbone therapy for use in combinations? Bruce D. Given, MD COO, Arrowhead Pharmaceuticals L.I.F.E.R. October 20, 2017 Safe Harbor Statement This presentation contains forward-looking
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationMyeloid Differentiation Observed, Including Induction of CD38 in 85% of Evaluable Patients
December 10, 2017 Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients Clinical
More informationCorporate Presentation
Corporate Presentation October 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine s current expectations
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationEnhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine
Enhanced Cancer Vaccine Effectiveness with NKTR-214, a CD122-Biased Cytokine Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics SMI Cancer Vaccines, September 2017 Nektar Therapeutics
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationmicrorna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease
microrna Therapeutics Harnessing the power of micrornas to target multiple pathways of disease January 2018 Safe Harbor Statement Statements contained in this presentation regarding matters that are not
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationEngineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
More information